A Search Service for Abbreviation / Long Form

■ Abbreviation / Long Form : Lp-PLA2 / lipoprotein-associated phospholipase A2

[Related PubMed/MEDLINE]
Total Number of Papers: 453
[Display Entries]
100 entries :
     (Publication year, Descending)
100 entries :
     (Publication year, Ascending)
>> all entries
[Entries Per Page]
 per page
Page Control
Page: of
Abbreviation:   Lp-PLA2  (>> Co-occurring Abbreviation)
Long Form:   lipoprotein-associated phospholipase A2
 Abbreviation Variation
 Long Form Variation
 Pair(Abbreviation/Long Form) Variation
No. Year Title Co-occurring Abbreviation
2020 Association of Serum Lipoprotein-Associated Phospholipase A2 and A379V Gene Polymorphisms with Carotid Plaques. CI, OR
2020 Biomarkers for Prediction of Cardiovascular Events in Community-Dwelling Adults Aged 40 or Older. CI, CVD, HRs, hs-CRP, IDI, NRI
2020 Calcific Aortic Valve Stenosis and Atherosclerotic Calcification. CAVS, OxPL
2020 Changes in extrapulmonary organs and serum enzyme biomarkers after chronic exposure to Buenos Aires air pollution. ALP, FA, PON1, UAP-BA
2020 Evaluation of lipoprotein-associated phospholipase A2, serum amyloid A, and fibrinogen as diagnostic biomarkers for patients with acute cerebral infarction. ACI, AUC, FIB, SAA
2020 Familial Combined Hyperlipidemia (FCH) Patients with High Triglyceride Levels Present with Worse Lipoprotein Function Than FCH Patients with Isolated Hypercholesterolemia. CRP, FCH, HDL, LDL, NTG
2020 Is Admission Lipoprotein-Associated Phospholipase A2 a Novel Predictor of Vasospasm and Outcome in Patients With Aneurysmal Subarachnoid Hemorrhage? aSAH, WFNS
2020 Lipoprotein-associated phospholipase A2: The story continues. ---
2020 Lp-PLA2 and dual antiplatelet agents in intracranial arterial stenosis. ICAS
10  2020 Metabolically unhealthy overweight individuals have high lysophosphatide levels, phospholipase activity, and oxidative stress. 8-epi-PGF2alpha, BMI, lysoPCs, lysoPEs, MHO, MUO, oxLDL, VFAs
11  2020 Phospholipase A2 is an Inflammatory Predictor in Cardiovascular Diseases: Is there any Spacious Room to Prove the Causation? ACS, CVD, LDL-C, sPLA2
12  2020 The Beneficial Effects of Alpha Lipoic Acid Supplementation on Lp-PLA2 Mass and Its Distribution between HDL and apoB-Containing Lipoproteins in Type 2 Diabetic Patients: A Randomized, Double-Blind, Placebo-Controlled Trial. ALA, ApoA1, CVD, FBS, HDL, oxLDL
13  2020 The relationship between dietary patterns and lipoprotein-associated phospholipase A2 levels in adults with cardiovascular risk factors: Tehran Lipid and Glucose Study. CVDs
14  2020 [Changes of serum lipoprotein-related phospholipase A2 in patients with white matter lesion based on KIM classification and its correlation with carotid atherosclerotic plaque]. CPI, DWML, ELISA, JCWML, JVWML, LDL-C, NC group, PVWML, TG, WML
15  2019 13-HODE, 9-HODE and ALOX15 as potential players in Rett syndrome OxInflammation. ALOX15, HODEs, PBMCs, RTT
16  2019 A 6-Week Worksite Positivity Program Leads to Greater Life Satisfaction, Decreased Inflammation, and a Greater Number of Employees With A1C Levels in Range. apoB, DHEA, HbA1c, hs-CRP, MPO, oxLDL, sdLDL
17  2019 ApoB, small-dense LDL-C, Lp(a), LpPLA2 activity, and cognitive change. apoB, CI, DSST, sdLDL-C, WFT
18  2019 Assessment of lipoprotein-associated phospholipase A2 level and its changes in the early stages as predictors of delayed cerebral ischemia in patients with aneurysmal subarachnoid hemorrhage. aSAH, AUC, CI, DCI, OR, WFNS
19  2019 Association between serum lipoprotein-associated phospholipase A2, ischemic modified albumin and acute coronary syndrome: a cross-sectional study. ACS, IMA, MACE, NSTEMI, STEMI, UA
20  2019 Butyphthalide in the treatment of massive Cerebral Infarction. ADL, NIHSS
21  2019 Chemiluminescence immunoassay for sensing lipoprotein-associated phospholipase A2 in cardiovascular risk evaluation. ---
22  2019 Effects of dl-3-n-butylphthalide on serum lipoprotein-associated phospholipase A2 and hypersensitive C-reactive protein levels in acute cerebral infarction. ACI, BI, hs-CRP, NBP, NIHSS
23  2019 Effects of Extended-Release Niacin on Quartile Lp-PLA2 Levels and Clinical Outcomes in Statin-treated Patients with Established Cardiovascular Disease and Low Baseline Levels of HDL-Cholesterol: Post Hoc Analysis of the AIM HIGH Trial. CV, ERN, HDL-C
24  2019 Energy Intake and Plasma Adiponectin as Potential Determinants of Lipoprotein-Associated Phospholipase A2 Activity: A Cross-Sectional Study. CVD, HDL, LDL, MetS
25  2019 Genetic contributors and soluble mediators in prediction of autoimmune comorbidity. Flt3L, IL, IRF8, LILRA3, MTHFR, PTH, SLE, SS, TNFAIP3, TREX1
26  2019 Icosapent ethyl reduces atherogenic markers in high-risk statin-treated patients with stage 3 chronic kidney disease and high triglycerides. CKD, CVD, eGFR, EPA, hs-CRP, LDL-C, oxLDL, TG
27  2019 Increased activity of lipoprotein-associated phospholipase A2 in non-severe asthma. ---
28  2019 Interleukin-6 and lipoprotein-associated phospholipase A2 are associated with functional trajectories. BI, IL-6, MI
29  2019 Iron Homeostasis Determines Fate of Human Pluripotent Stem Cells Via Glycerophospholipids-Epigenetic Circuit. hPSCs, PSCs
30  2019 Lipoprotein-Associated Phospholipase A2 Activity and Mass as Independent Risk Factor of Stroke: A Meta-Analysis. CI, RRs, SD
31  2019 Lipoprotein-associated phospholipase A2 is a risk factor for diabetic kidney disease. DKD, eGFR, T2D, UAER
32  2019 Lipoprotein-associated phospholipase A2 predicts cardiovascular events in dialyzed patients. CV
33  2019 Lipoprotein-associated phospholipase A2 predicts lower limb ischemia in hemodialysis subjects. HD
34  2019 Lp-PLA2 activity and mass and CRP are associated with incident symptomatic peripheral arterial disease. HR, PAD
35  2019 Lp-PLA2 as a promising predictor of comorbidities in patients with severe psoriasis. ---
36  2019 Lp-PLA2 as a risk factor of early neurological deterioration in acute ischemic stroke with TOAST type of large arterial atherosclerosis. END, LAA
37  2019 Lp-PLA2, a new biomarker of vascular disorders in metabolic diseases. MetS
38  2019 Mining possible associations of faecal A. muciniphila colonisation patterns with host adiposity and cardiometabolic markers in an adult population. NW, OW/OB, sCD14
39  2019 Performance Characteristics and Clinical Value of the Lipoprotein-Associated Phospholipase A2 by an Enzymatic Kinetic Method. CHD, CVs, TC
40  2019 Pharmacokinetics and exploratory efficacy biomarkers of bococizumab, an anti-PCSK9 monoclonal antibody, in hypercholesterolemic Japanese subjects
. HDL, LDL-C
41  2019 Plasma Lipoprotein-associated Phospholipase A2 and Superoxide Dismutase are Independent Predicators of Cognitive Impairment in Cerebral Small Vessel Disease Patients: Diagnosis and Assessment. CSVD, MMSE, MoCA, OLRGLMs, SOD, WMHs
42  2019 Relationship of visceral and subcutaneous adipose depots to markers of arterial injury and inflammation among individuals with HIV. CT, hs-CRP, hs-cTnT, oxLDL, PLWH, VAT
43  2019 Serum lipoprotein-associated phospholipase A2 as a promising prognostic biomarker in association with 90-day outcome of acute intracerebral hemorrhage. ICH, NIHSS
44  2019 Sympathoexcitation and impaired arterial baroreflex sensitivity are linked to vascular inflammation in individuals with elevated resting blood pressure. BP, BRS, ERBP, ICAM-1, MSNA, SNS
45  2019 Synthesis and Automated Labeling of [18F]Darapladib, a Lp-PLA2 Ligand, as Potential PET Imaging Tool of Atherosclerosis. PET
46  2019 The association between the D166E polymorphism of the lipoprotein associated phospholipase A2 and risk of myocardial infarction. MI
47  2019 The Utility of the Lipoprotein-Associated Phospholipase A2 (Lp-PLA2) Assay in Detecting Abnormalities in Lipid Metabolism and Cardiovascular Risk in an HIV-Infected South African Cohort. ART, CIMT, CVD, PI, PWH, VL
48  2018 Amelioration of atherosclerosis in apolipoprotein E-deficient mice by combined RNA interference of lipoprotein-associated phospholipase A2 and YKL-40. RNAi
49  2018 Association between high-sensitivity C-reactive protein, lipoprotein-associated phospholipase A2 and carotid atherosclerosis: A cross-sectional study. CI, hs-CRP, OR
50  2018 Association of lipoprotein-associated phospholipase A2 and risk of incident atrial fibrillation: Findings from 3 cohorts. AF, ARIC, CHS, HR, MESA
51  2018 Association of lipoprotein-associated phospholipase A2 mass with asymptomatic cerebral artery stenosis. ACAS, CAS, CI, ECAS, ELISA, ICAS, OR, TCD
52  2018 Association of Lipoprotein-Associated Phospholipase A2 with the Prevalence of Nonalcoholic Fatty Liver Disease: A Result from the APAC Study. NAFLD
53  2018 Atherosclerosis assessment and rheumatoid arthritis. CIMT, DAS28, DM, LDL
54  2018 Atypical Antipsychotic Administration in Schizophrenic Patients Leads to Elevated Lipoprotein-Associated Phospholipase A2 Levels and Increased Cardiovascular Risk: A Retrospective Cohort Study. AAP, CVD
55  2018 Catechin Attenuates Coronary Heart Disease in a Rat Model by Inhibiting Inflammation. CHD, IL, NF-kappaB, STAT, TNF-alpha
56  2018 Change in lipoprotein-associated phospholipase A2 and its association with cardiovascular outcomes in patients with acute coronary syndrome. ACS, CCU, CI, CK-MB, HR
57  2018 Change of Inflammatory Factors in Patients with Acute Coronary Syndrome. ACS, CHD, ICAM-1, SAP
58  2018 Chronic inhibition of lipoprotein-associated phospholipase A2 does not improve coronary endothelial function: A prospective, randomized-controlled trial. CED
59  2018 Consumption of a defined, plant-based diet reduces lipoprotein(a), inflammation, and other atherogenic lipoproteins and particles within 4 weeks. hs-CRP, IL-6, LDL
60  2018 Darapladib inhibits atherosclerosis development in type 2 diabetes mellitus Sprague-Dawley rat model. HE, ICAM-1, iNOS, LDL, lysoPC, oxNEFA, T2DM, T2DM-DP
61  2018 Differential expression of Lp-PLA2 in obesity and type 2 diabetes and the influence of lipids. AbdSc, CVD, iPLA2, oxLDL
62  2018 Effect of lipoprotein-associated phospholipase A2 inhibitor on insulin resistance in streptozotocin-induced diabetic pregnant rats. ELISA, FINS, FPG, HE, HOMA-IR, IR, ISI, STZ, TC, TG
63  2018 Effect of Selective Thrombus Aspiration on Serum Lipoprotein-Associated Phospholipase A2 in Patients with ST-Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention with High Thrombus Burden. HTB, PPCI, STEMI, TA
64  2018 Effects and potential mechanism of atorvastatin treatment on Lp-PLA2 in rats with dyslipidemia. CRP, LDL-C, NO, ROCK1, TC
65  2018 Elevated inflammatory Lp-PLA2 and IL-6 link e-waste Pb toxicity to cardiovascular risk factors in preschool children. BPbs, e-waste, HDL, IL, LDL/HDL, TG
66  2018 Exploration of serum sensitive biomarkers of fatty liver in dairy cows. FGF21, Hb, TAG
67  2018 HDL functionality and cardiovascular outcome among nondialysis chronic kidney disease patients. CKD, SAA
68  2018 Impact of a non-synonymous Q281R polymorphism on structure of human Lipoprotein-Associated Phospholipase A2 (Lp-PLA2 ). ED, LDL, MD, nsSNPs, ProSA, SVM, WT
69  2018 Impact of tyrosine nitration at positions Tyr307 and Tyr335 on structural dynamics of Lipoprotein-associated phospholipase A2-A therapeutically important cardiovascular biomarker for atherosclerosis. 3-NT, ED, MD, PAF, PTN
70  2018 Lipoprotein-associated phospholipase A2 activity in obese adolescents with and without type 2 diabetes. DPV, T2D
71  2018 Lipoprotein-associated Phospholipase A2 and Coronary Heart Disease. CHD
72  2018 Lipoprotein-Associated Phospholipase A2 and Risk of Carotid Atherosclerosis and Cardiovascular Events in Community-Based Older Adults in China. CI, CVD, HR, MI, OR
73  2018 Lipoprotein-associated phospholipase A2 and risk of incident peripheral arterial disease: Findings from The Atherosclerosis Risk in Communities study (ARIC). ARIC, CI, HR, PAD
74  2018 Lipoprotein-Associated Phospholipase A2 is Linked with Poor Cardio-Metabolic Profile in Patients with Ischemic Stroke: A Study of Effects of Statins. SR
75  2018 Lipoprotein-associated phospholipase A₂ activity is increased in patients with definite familial hypercholesterolemia compared with other forms of hypercholesterolemia. CVD, FH
76  2018 Long-term darapladib use does not affect coronary plaque composition assessed using multimodality intravascular imaging modalities: a randomized-controlled study. ---
77  2018 Lp-PLA2 activity is associated with increased risk of diabetic retinopathy: a longitudinal disease progression study. ---
78  2018 Measurement of Lipoprotein-Associated Phospholipase A2 by Use of 3 Different Methods: Exploration of Discordance between ELISA and Activity Assays. SISCAPA
79  2018 Met117 oxidation leads to enhanced flexibility of cardiovascular biomarker- lipoprotein- associated phospholipase A2 and reduced substrate binding affinity with platelet-activating factor. ED, LDL, MD, PAF
80  2018 Myeloperoxidase level and inflammatory markers and lipid and lipoprotein parameters in stable coronary artery disease. ACAD, ACS, hs-CRP, IL-6, MPO, SCAD, TNF-alpha
81  2018 Novel enzymatic method for assaying Lp-PLA2 in serum. PAF
82  2018 Oxidized phospholipids and lipoprotein-associated phospholipase A2 as important determinants of Lp(a) functionality and pathophysiological role. CAVS, CVD, LDL, OxPL
83  2018 Photoelectrochemical immunoassay of lipoprotein-associated phospholipase A2 via plasmon-enhanced energy transfer between gold nanoparticles and CdS QDs/g-C3N4. PEC, QDs
84  2018 Polyunsaturated Fatty Acids and Their Correlations with Parameters of Oxidative/Antioxidant Potential of the Blood and Lipoprotein-Associated Phospholipase A2 in Coronary Atherosclerosis. FORT
85  2018 Possible effects of lipoprotein-associated phospholipase A2 single-nucleotide polymorphisms on cardiovascular risk in patients with preeclampsia. CRP, CVD, PE, SAA
86  2018 Predictive value of combining the level of lipoprotein-associated phospholipase A2 and antithrombin III for acute coronary syndrome risk. ACS, ATIII, GRACE, OR
87  2018 Relation between lipoprotein-associated phospholipase A2 mass and incident ischemic stroke severity. NIHSS, ROC
88  2018 SERUM LIPOPROTEIN-ASSOCIATED PHOSPHOLIPASE A2 IN MALES WITH METABOLIC SYNDROME AND OBSTRUCTIVE SLEEP APNEA. AHI, CRP, CVD, MetS, OSAS
89  2018 The Prognostic Value of Lipoprotein-Associated Phospholipase A2 in the Long-Term Care of Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention. ACS, CI, PCI
90  2018 The relationship between lipoprotein-associated phospholipase A2 with cardiovascular risk factors in testosterone deficiency. ANOVA, BMI, hs-CRP, oxLDL, sdLDL, SHBG
91  2018 Usefulness of Lipoprotein-Associated Phospholipase A2 Activity and C-Reactive Protein in Identifying High-Risk Smokers for Atherosclerotic Cardiovascular Disease (from the Atherosclerosis Risk in Communities Study). ASCVD, hs-CRP
92  2018 [Association of serum lipoprotein-associated phospholipase A2 with vascular dementia after ischemic stroke]. VCIND, VD
93  2017 A red yeast rice-olive extract supplement reduces biomarkers of oxidative stress, OxLDL and Lp-PLA2, in subjects with metabolic syndrome: a randomised, double-blind, placebo-controlled trial. MDA, MetS, oxLDL
94  2017 AMP-activated protein kinase mediates the effects of lipoprotein-associated phospholipase A2 on endothelial dysfunction in atherosclerosis. AMPK, CAD, ET-1, HUVECs, ICAM-1, NO, oxLDL, PECAM-1
95  2017 Association between FSP, CVHI, inflammatory cytokines and the incidence of primary stroke. CVHI, FSP, hs-CRP, IL-6, TNF-alpha
96  2017 Association of Lp-PLA2 G994T gene polymorphism with risk of ischemic stroke in Chinese population. ---
97  2017 Associations among oxidative stress, Lp-PLA2 activity and arterial stiffness according to blood pressure status at a 3.5-year follow-up in subjects with prehypertension. baPWV, BP, oxLDL, SBP
98  2017 Atherogenic properties of LDL particles after switching from Truvada or Kivexa plus lopinavir/r to lamivudine plus lopinavir/r: OLE-MET substudy. LDL, NRTI
99  2017 Biological variability of lipoprotein-associated phospholipase A2 activity in healthy individuals. IoI, RCV
100  2017 Community-based statins and advanced carotid plaque: Role of CD163 positive macrophages in lipoprotein-associated phospholipase A2 activity in atherosclerotic plaque. ---